Recently, antimicrobial resistance among nontyphoid Salmonella serotypes has been increasingly recognized. In southern Taiwan, we encountered 3 cases of invasive infections caused by Salmonella enterica serotype Choleraesuis with resistance to ciprofloxacin and ceftriaxone. Resistance to ciprofloxacin was related to nucleotide mutations in gyrA and parC, and resistance to ceftriaxone was related to the presence of CMY-2 b-lactamase.
Nontyphoid Salmonella infections are a major public health issue and are reported to be increasingly frequent [1] . Recently, antimicrobial resistance in Salmonella serotypes has been recognized worldwide. Initially, the concern was focused on old antimicrobial drugs, such as ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole. Recently, there was another piece of bad news; namely, that Salmonella Typhi, Salmonella Paratyphi, and nontyphoid Salmonella enterica serotypes are increasingly found to be resistant to fluoroquinolones [2, 3] and extended-spectrum cephalosporins [2, 4] , rendering the second-line antimicrobials less reliable in certain clinical situations.
In this report, we highlight another concern about antimicrobial resistance among Salmonella serotypes: resistance to both fluoroquinolones and extended-spectrum cephalosporins.
A single Salmonella Choleraesuis isolate with such resistance in northern Taiwan has been described [5] . In this report, we describe 3 cases of community-acquired infection caused by S. Choleraesuis with this unusual resistance phenotype, and we discuss the rational therapeutic regimen.
Material and methods. From July 2003 to April 2004, 5 Salmonella isolates resistant to ciprofloxacin and ceftriaxone from a medical center in southern Taiwan were studied to determine their antimicrobial susceptibility, resistance mechanisms, and genetic relatedness. The serotypes of Salmonella serogroup C isolates were identified by use of somatic and flagellar antigens (Denka Seiken) [6] . Isolates were tested with Etest strips (AB Biodisk) to determine MIC values for 14 antimicrobial agents. The double-disk synergy method, which includes one disk of ceftazidime or cefotaxime and another of amoxicillin-clavulanate, was applied to detect whether the isolates produced extended-spectrum b-lactamase.
Isoelectric focusing was performed, according to procedures described elsewhere [7] . For PCR amplification of gyrA, gyrB parC, and parE, as primers described elsewhere [8] were used. The genes bla SHV , bla TEM-1 , bla CMY-2 , and bla CTX-M were detected by PCR with oligonucleotide primers, as has been previously described [7, 9] . DNA sequencing with PCR instruments was performed with an ABI 3730 DNA Analyzer (Applied Biosystems). For PFGE, the DNA was digested by the restriction enzymes XbaI and BlnI, as has been described elsewhere [6] . Patient 1. A 24-year-old homosexual man who had been infected with HIV-1 since 1988 and had not regularly received antiretroviral drug therapy presented to the hospital on 20 July 2003 with a 2-day history of fever and chills. The patient had bacteremia caused by S. Choleraesuis (isolate number S1-358); the isolate was resistant to cefpodoxime and ciprofloxacin but susceptible to ceftriaxone (by disc diffusion method). Therefore, parenteral ceftriaxone was administered for 2 days, and oral cefixime was given. After discharge from the hospital, the patient was poorly compliant to antiretroviral and antimicrobial therapies, and he had intermittent fever and occasional watery diarrhea. On 26 August 2003, fever recurred, and bacteremia due to S. Choleraesuis (S1-402) was documented again. At that time, his CD4 + cell count was 36 cells/mm 3 , and his plasma HIV-1 viral load was 18,400 copies/mL. After 2 weeks of oral cefixime therapy, he was lost to follow-up.
Patient 2.
An 81-year-old woman with non-insulindependent diabetes mellitus, hypertension, congestive heart failure, and atrial fibrillation regularly visited the cardiovascular clinic of our hospital. Antimicrobial therapy was never admin- istered at those visits. On 13 September 2003, S. Choleraesuis (isolate number S1-407) was found in her blood and urine during an examination prompted by a 2-day history of fever and chills. The patient left the hospital without receiving medication specific for Salmonella bacteremia. On 17 October 2003, progressive dyspnea and chest discomfort developed in the patient, and endotracheal intubation was performed to relieve respiratory distress. On examination, S. Choleraesuis was discovered in her blood and urine. Magnetic resonance angiography revealed a mycotic aneurysm with a diameter of 2 cm in her right renal artery. Surgical intervention was deferred by her family because of the high risk. Oligouric acute renal failure developed, and the patient received regular hemodialysis. The patient was treated with 1 g of parenteral cefepime per day for 8 weeks. She died at the end of 2003, however, of septic shock due to S. Choleraesuis bacteremia. All S. Choleraesuis isolates associated with these complications had the same antibiogram.
Patient 3. On 8 October 2003, a 53-year-old man with non-insulin-dependent diabetes mellitus was hospitalized because of a 2-day history of fever. He had bacteremia caused by S. Choleraesuis (isolate number S1-9210131), which was resistant to ciprofloxacin and cefpodoxime but susceptible to ceftriaxone (by the disc-diffusion method). Abdominal CT scanning performed on 10 October did not reveal any structural abnormality. The patient was treated with parenteral ceftriaxone for 1 week and oral cefixime for an additional week. However, he developed high fever, altered consciousness, and hypotension on 1 December. S. Choleraesuis bacteremia was documented again, and the isolated strain (isolate number S-9212061) was intermediately susceptible to ceftriaxone. A mycotic aneurysm with a diameter of 2 cm in his left common iliac artery with involvement of left psoas muscle was revealed by magnetic resonance angiography. Extensive debridement, aneurysmectomy, and a femoral-to-femoral bypass with a Gortex graft were performed. S. Choleraesuis was isolated from dissected tissues. Because of persistent, vague low-back discomfort, spinal MRI was performed on 17 December and revealed bulging of discs L3-4 and L4-5. Parenteral cefepime was administered for 7 weeks. The patient was discharged without a prescription for oral antibiotic therapy on 20 January 2004. Two weeks later, he was hospitalized again because of recurring fever and chills. S. Choleraesuis bacteremia was noted on 5 February 2004. Abdominal CT scanning revealed an intact left common iliac artery, but Tc-99m methylene diphosphonate bone scanning discovered discitis in L4-5. Thereafter, imipenem-cilastatin was administered at a dosage of 0.5 g every 6 h for 6 weeks. During hospitalization, 6 sets of blood cultures were sterile. The patient remained afebrile and was free of low back pain at 4 months after discharge.
All 5 Salmonella isolates from these 3 patients were identified as S. Choleraesuis. The MIC values of 14 antimicrobial agents, as determined by the use of Etest strips, are shown in table 1. All isolates were resistant to ceftriaxone, amipicillin, trimethoprim-sulfamethoxazole, and ciprofloxacin but susceptible to cefepime, carbapenems, and aztreonam. Although NCCLS does not have a recommended interpretive standard, the MIC of cefpirome was q0.5 mg/mL, which we reasonably regarded as indicating susceptibility to cefpirome. None of the isolates exhibited the extended-spectrum b-lactamase-resistance phenotype, according to the double disk-diffusion method.
Isoelectric focusing showed that 5 isolates expressed a blactamase with a focus at pI 9.0, corresponding to a CMY-2-like b-lactamase. All isolates except S1-407 expressed another b-lactamase with a focus at pI 5.4, corresponding to a TEM-1-like b-lactamase. Of the relevant b-lactamase genes, only bla CMY-2 was detected in all isolates, and bla TEM was noted in all isolates except S1-407. Sequence analysis of the bla CMY-2 -like DNA fragments showed that the amplicon sequences from 5 isolates were the same and that they were identical to the homologous region of bla CMY-2 . In addition, major regions of gyrA, gyrB, parC , and parE were sequenced. In comparison with the corresponding nucleotide sequences of fluoroquinolone-susceptible Salmonella strains, 2 base-substitutions in gyrA (Ser83Phe and Asp87Asn) and parC (Thr57Ser and Ser80Ile) were identified, and no change in amino acid sequences in gyrB or parE was found. As for PFGE genotyping with either Xba1 or BlnI, only 1 genotype was noted ( figure 1a and figure 1b) .
Discussion. Resistance to ceftriaxone and to cefotaxime in Salmonella serotypes has been increasingly recognized, and is related to presence of plasmid-mediated AmpC-type enzymes or extended-spectrum b-lactamases [2] . In Taiwan, CTX-M-3 [10] and CMY-2 [7] have been identified in extended-spectrum cephalosporin-resistant Salmonella species. The patients we describe acquired S. Choleraesuis infection in the community, and all etiological agents harboring bla CMY-2 were closely related in genetic clones. Together with the findings of earlier studies [7, 11] , our findings suggest that the emergence of the unusual resistant phenotype results from the spread of a specific S. Choleraesuis clone that has acquired the bal CMY -containing resistance determinant from enterobacteria in the community. Salmonella isolates from our study that were highly resistant to ciprofloxacin were found to have 2 base-substitutions in gyrA (Ser83Phe and Asp87Asn) and 1 in parC (Ser80Ile), which have been observed in quinolone-resistant strains of Salmonella [3, 6] . It has been recognized that strains with 11 mutation in gyrA or у1 mutations in both gyrA and parC will be more resistant to quinolones [3] . However, it is worth mentioning that among Salmonella pathogens, the degree of quinolone resistance will be greater if nalidixic acid resistance is taken into account or if the fluoroquinolone breakpoints are revised [12] .
Clinical data on the use of carbapenems against invasive Salmonella infection is limited. Imipenem therapy has cured an infant with Salmonella meningitis, who had relapse after 1 month of cefotaxime therapy [13] , and patient 3 in our report, who had spinal osteomyelitis that relapsed after 7 weeks of cefepime therapy. However, the potential role of carbapenems in the treatment of Salmonella infections warrants further clinical studies.
The cases we describe highlight the therapeutic challenge resulting from antimicrobial resistance to ciprofloxacin and ceftriaxone, which compromises the therapeutic choices and the clinical outcome. In a case-control cohort study from Denmark, the 2-year death rate for people infected with Salmonella strains resistant to ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline was 4.8 times higher than that of the general population, and the 2-year death rate for people infected with Salmonella strains with nalidixic acid resistance was 10.3 times higher [14] . It is very likely that the emergence of resistance to both ciprofloxacin and ceftriaxone will further decrease survival among infected patients.
